Patient Experience Data: US FDA’s Evidentiary Standards Should Reflect Intended Use

Degree of rigor may vary depending upon intended use of the data throughout a drug’s lifecycle, stakeholders say in comments on FDA’s first patient-focused drug development draft guidance; industry and advocates push for clarity on interactions to discuss patient experience studies with FDA staff and the promotional implications of such data.

The US FDA should clarify the level of rigor needed for collecting patient experience data based upon how that information will be used in a drug’s development, industry and advocacy groups tell the agency.

In comments on a June draft guidance on collecting comprehensive and representative input, stakeholders pressed FDA to better define the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Approval Standards

Non-Opioid Analgesics Guidance On Chronic Pain: One Trial Plus Confirmatory Evidence May Be Enough

 

Alternative therapies designed to avoid, eliminate, or reduce the use of opioids may be eligible for Breakthrough Therapy Designation or Priority Review, the US FDA draft guidance says.

‘We Are Not The Dark Side Of The Force’ – EU Regulator Urges ATMP Firms To Use Advice Services

 

While drug regulators are “conservative” by nature, the European Medicines Agency wants to help companies rather than rip their dossiers “into little pieces,” a senior regulatory assessor says.

Europe’s EDQM To Help New African Medicines Agency Boost Quality Framework

 

Drawing on around 60 years of experience, the European Directorate for the Quality of Medicines & HealthCare will help the newly formed African Medicines Agency develop robust quality control systems.

US FDA’s Tidmarsh Takes On Surrogate Endpoints, Maybe Old Business Partner, On LinkedIn

 

CDER Director George Tidmarsh said in a now deleted social media post that his center will evaluate surrogate endpoints. Tidmarsh mentioned "notable failures," including a lupus drug, where he has past business connections to the sponsor's board chair.

More from Pathways & Standards

October US FDA User Fee Goals: Few Novel Agents, But Many New Indications As Shutdown Looms

 

October is unusually low on user fee goals for novel agents, but more than 20 applications for new indications and formulations will keep FDA staff busy, especially in oncology and ophthalmology.

Europe’s EDQM To Help New African Medicines Agency Boost Quality Framework

 

Drawing on around 60 years of experience, the European Directorate for the Quality of Medicines & HealthCare will help the newly formed African Medicines Agency develop robust quality control systems.

US FDA’s Tidmarsh Takes On Surrogate Endpoints, Maybe Old Business Partner, On LinkedIn

 

CDER Director George Tidmarsh said in a now deleted social media post that his center will evaluate surrogate endpoints. Tidmarsh mentioned "notable failures," including a lupus drug, where he has past business connections to the sponsor's board chair.